II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Retained Earnings

Last Annual Value

-230.05M

3-Year CAGR

-2%

5-Year CAGR

-16%

10-Year CAGR

-16%

II

ImageneBio Inc Competitors Analysis of Retained Earnings

IMA · NASDAQ
CompanyRetained Earnings
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
-230.05M
N/AN/AN/A 
-376.47M
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
-614.70M
N/AN/AN/A
-128.79M
N/AN/AN/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
-608.57M
N/AN/AN/A
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
-38.46M
N/AN/AN/A
-127.83M
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-460.19M
N/AN/AN/A
-977.96M
N/AN/AN/A
-321.71M
N/AN/AN/A
-160.00M
N/AN/AN/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69